{"id":"W4385651241","doi":"10.1016/s2352-3018(23)00136-4","title":"Efficacy, safety, and tolerability of switching to long-acting cabotegravir plus rilpivirine versus continuing fixed-dose bictegravir, emtricitabine, and tenofovir alafenamide in virologically suppressed adults with HIV, 12-month results (SOLAR): a randomised, open-label, phase 3b, non-inferiority trial","year":2023,"lang":"en","type":"article","venue":"The Lancet HIV","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":115,"is_retracted":false,"has_abstract":false,"ca_institutions":"University Health Network","funders":"ViiV Healthcare","keywords":"Emtricitabine; Rilpivirine; Medicine; Tenofovir alafenamide; Dolutegravir; Internal medicine; Population; Tolerability; Adverse effect; Human immunodeficiency virus (HIV); Virology; Viral load; Antiretroviral therapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002053385,0.001417869,0.001943895,0.0002913817,0.0003577885,0.001312538,0.0008573299,0.002088224,0.007243269],"category_scores_gemma":[0.002431519,0.0005331572,0.001824538,0.0002968419,0.001228443,0.001532987,0.0003413688,0.003647688,0.001017306],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0008201516,"about_ca_system_score_gemma":0.0006298615,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001052633,"about_ca_topic_score_gemma":0.00170642,"domain_scores_codex":[0.9990244,0.0005001489,0.00005627572,0.0001880238,0.00006829269,0.0001628067],"domain_scores_gemma":[0.998542,0.0005655916,0.0002980583,0.0001300405,0.00005990162,0.0004045209],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9784268,0.005139005,0.0008395398,0.0001571828,0.0004566436,0.00002037232,0.00006298387,0.0002308853,0.001705489,0.00004772547,0.0003130481,0.01260024],"study_design_scores_gemma":[0.8694625,0.1226418,0.005603677,0.00002762991,0.0005270074,0.00005073352,0.00004513172,0.0005363613,0.0005510966,0.000222007,0.0003084735,0.00002347408],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9966948,0.001161841,0.000116887,0.000241275,0.0001115095,0.0003075187,0.0003812815,0.00003292896,0.0009518729],"genre_scores_gemma":[0.9966289,0.0005107961,0.0003696309,0.0004140267,0.000196625,0.000365875,0.0004267547,0.00001445798,0.001072915],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.007243269,"threshold_uncertainty_score":0.0242312,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.03948339338740951,"score_gpt":0.3262576267493967,"score_spread":0.2867742333619872,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}